Researchers have developed a feline version of Cetuximab with therapeutic potential against feline oral squamous cell carcinoma, according to a study published online 9 October 2026 in The Veterinary Journal.

The paper, authored by Gennaro Altamura, Arianna Finizio, Alessandra Napolano, Chiara Capasso, Maddalena Raia, Emanuele Sasso, Nicola Zambrano and Giuseppe Borzacchiello, reports the engineering and preclinical evaluation of a cat-adapted counterpart of the anti-EGFR monoclonal antibody Cetuximab.

Why target this tumour?

Oral squamous cell carcinoma is among the most common and most difficult-to-treat malignancies in cats. Current options — surgery, radiation therapy and chemotherapy — frequently fail to control locally advanced disease, and prognosis remains poor.

Cetuximab targets the epidermal growth factor receptor (EGFR), a pathway implicated in tumour growth. The human drug is not registered for use in cats; the study team set out to create a feline-compatible antibody designed to work in this species and evaluated its therapeutic potential against feline oral squamous cell carcinoma in the laboratory.

What changes at the exam table?

For now, nothing is approved. The compound is an experimental candidate, and no regulatory body — FDA CVM, EMA or USDA — has authorised a feline Cetuximab for clinical use. Veterinarians managing cats with oral squamous cell carcinoma should continue to follow established protocols while monitoring this development.

The study's significance is translational: it demonstrates that a species-adapted targeted antibody against this cancer is feasible, opening a path toward clinical trials. Any move from bench to bedside would require formal safety and efficacy testing in client-owned cats before regulators review a marketing application.

Companion-animal implications

A validated feline anti-EGFR antibody would give oncologists a targeted option for a tumour that responds poorly to conventional therapy. Because the antibody is engineered specifically for cats, it would also be expected to reduce the immunogenicity problems that limit use of human or mouse antibodies in feline patients.

What comes next?

The authors' work, published 9 October 2026, positions the feline Cetuximab candidate for further preclinical development; the next step toward practice-level impact would be controlled clinical evaluation in cats with naturally occurring oral squamous cell carcinoma.